Investigating the Impact of a Shared Decision-Making Tool
2 other identifiers
interventional
105
1 country
3
Brief Summary
The purpose of this research study is to learn more about how the use of a Shared Decision-Making Tool (SDMT) will impact a patient's decision-making to pursue treatment for knee osteoarthritis.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P50-P75 for not_applicable
Started Apr 2023
Shorter than P25 for not_applicable
3 active sites
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
June 6, 2022
CompletedFirst Posted
Study publicly available on registry
June 9, 2022
CompletedStudy Start
First participant enrolled
April 15, 2023
CompletedPrimary Completion
Last participant's last visit for primary outcome
September 20, 2023
CompletedStudy Completion
Last participant's last visit for all outcomes
September 20, 2023
CompletedJanuary 18, 2024
January 1, 2024
5 months
June 6, 2022
January 16, 2024
Conditions
Outcome Measures
Primary Outcomes (1)
Change in Impact of the shared decision-making tool on a patient's willingness to seek treatment for knee osteoarthritis
The primary objective is to assess the impact of the shared decision-making tool on a patient's decision to seek treatment for knee osteoarthritis. This will be assessed using a survey with a 5-point scale that asks several questions about a patient's willingness to pursue specific treatment options (1 = not at all willing, 5 = completely willing). The change over time is assessed to see if the intervention changes the patient's willingness to consider different treatment options. To assess change a baseline survey, a survey immediately after the intervention, and survey 4 weeks later will be collected. Change = (Week 4 - Baseline) and Change = (Immediately after intervention - Baseline) and Change = (Week 4 - Immediately after intervention).
Baseline, Immediately after intervention, and Week 4
Secondary Outcomes (2)
Change in Impact of SDMT on patient understanding
Baseline, Immediately after intervention, and Week 4
Change in Impact of SDMT on decision-making
Baseline, Immediately after intervention, and Week 4
Study Arms (2)
Control
OTHERPatients in the control arm of the study will watch a short video and then receive standard of care counseling with an orthopaedic surgeon.
Shared Decision-Making Tool
EXPERIMENTALPatients in the treatment arm of the study will watch a short video and then receive standard of care counseling with an orthopaedic surgeon that includes discussion of the shared decision-making tool.
Interventions
The Shared Decision-Making Tool (SDMT) is designed to provide a personalized, patient- centered framework for clinical discussions regarding treatment options for knee osteoarthritis. The tool functions through patient input of information such as pain severity and current symptoms, alongside other demographic information such as age, race, and comorbidities, to offer a series of outcomes to better illustrate how the patient's specific disease presentation will progress. Ultimately, using the SDMT may impact patient behavior if patients change their treatment preferences after utilizing the tool. This can empower them to seek additional support over time and maintain communication with their orthopedist to ensure they are on a healthier path.
Short video that describes knee osteoarthritis and possible treatment options.
Standard of care counseling for a patient presenting with knee osteoarthritis.
Eligibility Criteria
You may qualify if:
- age 45-64
- mild to moderate knee pain consistent with a diagnosis of osteoarthritis
You may not qualify if:
- known inflammatory disease diagnosis (ex. Lupus, Sjogren, or rheumatoid arthritis, prior knee replacement, acute knee trauma)
- BMI over 45
- persons from vulnerable populations
Contact the study team to confirm eligibility.
Sponsors & Collaborators
- Yale Universitylead
Study Sites (3)
Yale Medicine Multispecialty
Guilford, Connecticut, 06437, United States
Yale Ortho Milford
Milford, Connecticut, 06461, United States
Yale Ortho
New Haven, Connecticut, 06519, United States
Related Publications (4)
Hsu H, Siwiec RM. Knee Osteoarthritis. 2023 Jun 26. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2025 Jan-. Available from http://www.ncbi.nlm.nih.gov/books/NBK507884/
PMID: 29939661BACKGROUNDJohnson CB. A Personalized Shared Decision-Making Tool for Osteoarthritis Management of the Knee. Orthop Nurs. 2021 Mar-Apr 01;40(2):64-70. doi: 10.1097/NOR.0000000000000739.
PMID: 33756532BACKGROUNDKatz JN, Arant KR, Loeser RF. Diagnosis and Treatment of Hip and Knee Osteoarthritis: A Review. JAMA. 2021 Feb 9;325(6):568-578. doi: 10.1001/jama.2020.22171.
PMID: 33560326BACKGROUNDMarcelin JR, Siraj DS, Victor R, Kotadia S, Maldonado YA. The Impact of Unconscious Bias in Healthcare: How to Recognize and Mitigate It. J Infect Dis. 2019 Aug 20;220(220 Suppl 2):S62-S73. doi: 10.1093/infdis/jiz214.
PMID: 31430386BACKGROUND
MeSH Terms
Conditions
Interventions
Condition Hierarchy (Ancestors)
Intervention Hierarchy (Ancestors)
Study Officials
- PRINCIPAL INVESTIGATOR
Daniel H Wiznia, MD
Yale University
Study Design
- Study Type
- interventional
- Phase
- not applicable
- Allocation
- RANDOMIZED
- Masking
- SINGLE
- Who Masked
- PARTICIPANT
- Purpose
- OTHER
- Intervention Model
- PARALLEL
- Sponsor Type
- OTHER
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
June 6, 2022
First Posted
June 9, 2022
Study Start
April 15, 2023
Primary Completion
September 20, 2023
Study Completion
September 20, 2023
Last Updated
January 18, 2024
Record last verified: 2024-01
Data Sharing
- IPD Sharing
- Will share
- Shared Documents
- STUDY PROTOCOL, ICF
- Time Frame
- De-identified data will be kept for 5 years after the data is collected.
- Access Criteria
- Researchers involved in the project will discuss access with the principal investigator.
De-identified patient data will be available to other researchers who assist study preparation for publication.